505 Penobscot Drive,
Redwood City, California 94063
Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus.
Genelabs Technologies was acquired by GlaxoSmithKline on October 29, 2008.
Join Mergr to view all 124 acquisitions of life science companies in 2008, including 20 acquisitions by private equity firms, and 104 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2008. The largest life science acquisition in 2008 was Alpharma Pharmaceuticals - which was acquired by King Pharmaceuticals for $16.0B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Genelabs Technologies.
No obligation. Cancel anytime.